We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRN icon
276
Stride
LRN
$4.16B
– –
-5,746
Closed -$490K
LTC
277
LTC Properties
LTC
$2.13B
– –
-10,014
Closed -$367K
LTH icon
278
Life Time Group Holdings
LTH
$10.2B
– –
-47,343
Closed -$1.16M
LXRX icon
279
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-156,860
Closed -$246K
MA icon
280
Mastercard
MA
$498B
– –
-1,280
Closed -$632K
MATV icon
281
Mativ Holdings
MATV
$479M
– –
-68,020
Closed -$1.16M
MAX icon
282
MediaAlpha
MAX
$746M
– –
-48,093
Closed -$871K
MDXG icon
283
MiMedx Group
MDXG
$630M
– –
-92,514
Closed -$547K
MED icon
284
Medifast
MED
$107M
– –
-17,267
Closed -$330K
MITK icon
285
Mitek Systems
MITK
$756M
– –
-68,913
Closed -$597K
MKSI icon
286
MKS Inc
MKSI
$17.4B
– –
-5,541
Closed -$602K
MLAB icon
287
Mesa Laboratories
MLAB
$551M
– –
-19,664
Closed -$2.55M
MMM icon
288
3M
MMM
$91.8B
– –
-8,875
Closed -$1.21M
MMS icon
289
Maximus
MMS
$3.32B
– –
-15,377
Closed -$1.43M
MMSI icon
290
Merit Medical Systems
MMSI
$4.82B
– –
-2,697
Closed -$267K
MNKD icon
291
MannKind Corp
MNKD
$1.19B
– –
-182,776
Closed -$1.15M
MODV
292
DELISTED
ModivCare
MODV
– –
-56,686
Closed -$809K
MPLX icon
293
MPLX
MPLX
$58.6B
– –
-6,846
Closed -$304K
MRCY icon
294
Mercury Systems
MRCY
$5.41B
– –
-23,851
Closed -$882K
MRK icon
295
Merck
MRK
$322B
– –
-8,482
Closed -$963K
MRVL icon
296
Marvell Technology
MRVL
$147B
– –
-10,840
Closed -$782K
MS icon
297
Morgan Stanley
MS
$319B
– –
-6,049
Closed -$631K
MSFT icon
298
Microsoft
MSFT
$2.9T
– –
-885
Closed -$381K
MTD icon
299
Mettler-Toledo International
MTD
$28.1B
– –
-165
Closed -$247K
MU icon
300
Micron Technology
MU
$835B
– –
-8,627
Closed -$895K
10 11
12
13 14

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.